Corcept Therapeutics (CORT) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.92 -0.67%
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of ($0.02), $0.04 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $9.01 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Oracle raises full year profit guidance, stock rises after hours
- Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
